Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
Journal of Asthma and Allergy · 2026-03 · Volume 19 · 1-14
DOI: 10.2147/jaa.s568990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-03. Verfasst von Muhammad Adrish und 6 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine, Houston, TX, USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Baylor College of Medicine, Houston, TX, USA.
- AstraZeneca, Wilmington, DE, USA.
- Inovalon, Bowie, MD, USA.
ORCID-Profile: Muhammad Adrish
Zitieren
APA
Adrish, M., DeMartino, J. K., Carstens, D., Jackson, M., Schinkel, J., Wilson, K., & Tkacz, J. (2026). Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study. Journal of Asthma and Allergy, Volume 19, 1-14. https://doi.org/10.2147/jaa.s568990
Vancouver
Adrish M, DeMartino JK, Carstens D, Jackson M, Schinkel J, Wilson K, et al. Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study. Journal of Asthma and Allergy. 2026;Volume 19:1-14. doi:10.2147/jaa.s568990
BibTeX
@article{Adrish2026,
author = {Adrish, Muhammad and DeMartino, Jessica K and Carstens, Donna and Jackson, Mandy and Schinkel, Jill and Wilson, Kathleen and Tkacz, Joseph},
title = {Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study},
journal = {Journal of Asthma and Allergy},
year = {2026},
volume = {Volume 19},
pages = {1--14},
doi = {10.2147/jaa.s568990}
}
EUVIMED